AngioDynamics is closing out fiscal 2026 with a powerhouse performance, fueled by 18% growth in its MedTech segment—driven by rising demand in cardiovascular and interventional oncology. Despite unexpected tariffs, profitability surged thanks to disciplined execution. Ahead, major catalysts loom: the AlphaReturn Blood Management System is in a pivotal trial, AngioVac Right Heart is poised for long-term growth, and NanoKnife—especially for prostate procedures—hit record highs in Q4 with surging physician adoption. The company’s purpose-driven strategy targets real clinical needs, delivering value to patients, doctors, and investors. Backed by a cash-generating device business, AngioDynamics is investing in clinical validation, securing key CPT codes and Medicare coverage for NanoKnife, and positioning itself for sustained expansion—even as CEO prepares for retirement in early 2027.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
